Tilray Exports Medical Cannabis to South Africa
With this announcement, Tilray products are now available in nine countries on five continents. This export is another strategic milestone as we aim to build the worlds leading medical cannabis brand, said Brendan Kennedy, Tilray CEO. We are encouraged by the evolving regulations pertaining to cannabis in South Africa and around the world and are pleased to make our pharmaceutical-grade products available to qualified patients in need in throughout the country.
Tilrays medical cannabis product in South Africa is a GMP-manufactured, full-spectrum oral solution featuring a balanced ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD). The product is available to qualified patients under South Africas named patient program. Through that program, authorized practitioners can apply for permission to access and prescribe unregistered medicines, including Tilray product, when intending to treat individual patients for specific conditions where certain registered medicines have failed. The product will then be distributed to patients through authorized distribution channels.
In South Africa, Tilray is proud to partner with BGM Pharmaceuticals, a locally-owned biotechnology company with a focus on providing innovative medical solutions to improve patient health outcomes in Africa. BGM is a level 1 Broad Based Black Economic Empowerment (BBBEE) research-focused company.